NCT06484634View on ClinicalTrials.gov

Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

NACompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2024

Conditions
Pregnancy Loss
Interventions
DRUG

Low molecular weight heparin

A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.

Trial Locations (1)

32200

DG Khan Hospital, Dera Ghazi Khan

All Listed Sponsors
lead

RESnTEC, Institute of Research

OTHER

NCT06484634 - Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss | Biotech Hunter | Biotech Hunter